Equities Analysts Issue Forecasts for NMRA Q2 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Tuesday, May 13th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.44) per share for the quarter, down from their prior estimate of ($0.42). HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics' Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($1.44) EPS and FY2029 earnings at ($0.23) EPS.

NMRA has been the subject of a number of other reports. Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. William Blair cut Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, March 10th. Royal Bank of Canada restated a "sector perform" rating and issued a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Guggenheim cut Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, March 7th. Finally, Stifel Nicolaus cut shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and decreased their target price for the company from $6.00 to $2.00 in a research note on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $9.29.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock traded up $0.03 during mid-day trading on Thursday, reaching $0.72. The company's stock had a trading volume of 324,683 shares, compared to its average volume of 2,461,381. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $17.19. The business's 50 day simple moving average is $0.83 and its 200 day simple moving average is $4.17. The company has a market capitalization of $116.30 million, a price-to-earnings ratio of -0.38 and a beta of 2.96.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02).

Institutional Investors Weigh In On Neumora Therapeutics

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of Neumora Therapeutics by 2.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company's stock worth $851,000 after buying an additional 1,629 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Neumora Therapeutics during the fourth quarter valued at about $363,000. SkyOak Wealth LLC raised its holdings in Neumora Therapeutics by 33.3% in the 4th quarter. SkyOak Wealth LLC now owns 20,000 shares of the company's stock valued at $212,000 after buying an additional 5,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Neumora Therapeutics in the 4th quarter valued at approximately $61,000. Finally, Windmill Hill Asset Management Ltd lifted its holdings in shares of Neumora Therapeutics by 299.6% during the fourth quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company's stock worth $1,106,000 after purchasing an additional 78,252 shares during the period. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.